Title: Preclinical activity and safety of STRO-004, a novel ADC targeting tissue factor for solid tumors

Abstract: #1572
Session: PO.ET02.01 – Antibody-Based Cancer Therapeutics 1

Date & Time: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CT
Presenter: Alice Yam, Ph.D., Vice President of Drug Discovery at Sutro Biopharma

Title: Enhancing Topo1i ADC efficacy: development of homogeneous dual-payload ADCs combining Topo1i with microtubule inhibitors or PARP inhibitors

Abstract: #2870
Session: PO.ET02.11 – Antibody-Based Cancer Therapeutics 2

Date & Time: Monday, April 28, 2025, 2:00 p.m. – 5:00 p.m. CT
Presenter: Gang Yin, Ph.D., Vice President of Platform Engineering & Process Research at Sutro Biopharma

Title: Anti-FRα antibody-drug conjugate luveltamab tazevibulin for the treatment of FRα-expressing non-small cell lung cancer

Abstract: #3299

Session: PO.CL01.09 – Predictive Biomarkers 4

Date & Time: Monday, April 28, 2028, 2:00 p.m. – 5:00 p.m. CT
Presenter: Genevive Hernandez, Ph.D., Executive Director, Biomarker Research & Translational Science at Sutro Biopharma